BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32271367)

  • 1. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
    Cercek A; Jarnagin WR
    JAMA Oncol; 2020 Jun; 6(6):935-936. PubMed ID: 32271367
    [No Abstract]   [Full Text] [Related]  

  • 2. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
    Yang X; Pan J; Zhao H
    JAMA Oncol; 2020 Jun; 6(6):935. PubMed ID: 32271359
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
    JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
    Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
    Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
    Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
    Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
    Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
    [No Abstract]   [Full Text] [Related]  

  • 7. Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
    Kang MH; Lee WS; Go SI; Kim MJ; Lee US; Choi HJ; Kim DC; Lee JH; Kim HG; Bae KS; Cho JM
    Medicine (Baltimore); 2014 Dec; 93(28):e305. PubMed ID: 25526478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
    Bran DM; Fuks D; Lansier A; Gallois C; Karoui M; Taieb J; Lahlou W
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101920. PubMed ID: 35390538
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
    Kim SH; Kim IH; Kim SW; Lee SO
    World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
    Chang Y; Mbeo G; Littman SJ
    J Gastrointest Cancer; 2012 Sep; 43(3):505-7. PubMed ID: 21556724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.
    Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Arihiro K; Takahashi S
    Clin J Gastroenterol; 2022 Dec; 15(6):1164-1168. PubMed ID: 36181621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
    Takahashi D; Mizuno T; Ebata T
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e29. PubMed ID: 34748277
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Jeong H; Yoo C;
    Hepatology; 2023 Oct; 78(4):E74-E75. PubMed ID: 37459559
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
    Marciano R; Servetto A; Bianco C; Bianco R
    J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
    Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL
    Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625
    [No Abstract]   [Full Text] [Related]  

  • 19. [A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
    Tamura T; Mizuyama Y; Shinto O; Nishihara T; Nakagawa H; Ono Y
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2732-4. PubMed ID: 21224695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surgical Resection after Gemcitabine plus Cisplatin Chemotherapy for Intrahepatic Cholangiocarcinoma with Multiple Lymph Node Metastases - Report of a Case].
    Otani T; Sakata J; Kameyama H; Otani A; Hirose Y; Tamura H; Morimoto Y; Miura K; Yoshino K; Kido T; Kobayashi T; Endo K; Wakai T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1764-1766. PubMed ID: 28133124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.